Share Name Share Symbol Market Type
Unilever PLC EU:UNA Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 46.205 46.00 46.37 0.00 06:15:05

Arecor's Insulin Candidate Achieves Positive Results in Phase 1 Trial

20/09/2021 8:31am

Dow Jones News

Unilever (EU:UNA)
Historical Stock Chart

From Jul 2021 to Jan 2022

Click Here for more Unilever Charts.

By Anthony O. Goriainoff


Arecor Therapeutics PLC said Monday that its insulin candidate for diabetes, AT278, met all primary and secondary endpoints with positive headline results from the Phase 1 clinical trial.

The London-listed biopharmaceutical company--backed by Unilever PLC--said AT278 had the potential to significantly improve post prandial glucose control and reduce the injection volume and/or number of daily injections of people with diabetes who have a high daily insulin need.

"These positive data for AT278, the second product in our diabetes franchise, follow the earlier positive results from the Phase I clinical trial of AT247... Together they position Arecor with a unique combination of ultra-concentrated and ultra-rapid insulin candidates offering the potential to meet the broad needs of patients across the growing diabetes market," Chief Executive Sarah Howell said.


Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com


(END) Dow Jones Newswires

September 20, 2021 03:16 ET (07:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Unilever Chart

1 Year Unilever Chart

1 Month Unilever Chart

1 Month Unilever Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220128 07:14:01